{"id":"6ff15a87-ca86-5972-8b56-4dfbfc262659","stable_key":"773f772e-bf8e-5e52-a2a2-6dd694d67f5d:bromelain-diabetes-rct-null","predicate":"does_not_significantly_change","statement":"In 68 adults with diabetes, 1050 mg/day bromelain for 12 weeks did not significantly improve fibrinogen, lipids, blood pressure, glucose, C-reactive protein, or anthropometric measures versus placebo.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"b498fe6f-5fc9-529d-84a8-03d10827e9ba","mechanism_event_label":"In 68 adults with diabetes, 1050 mg/day bromelain for 12 weeks did not significantly improve fibrinogen, lipids, blood pressure, glucose, C-reactive protein, or anthropometric measures versus placebo.","subject":{"id":"6a3990e6-85af-58c7-8087-8a251db842fa","slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"},"object":{"id":"85b123d4-03ab-5e8e-98c3-03faec633ea6","slug":"human-diabetes-cardiovascular-risk-panel","display_name":"Cardiovascular risk markers in adults with diabetes","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"b498fe6f-5fc9-529d-84a8-03d10827e9ba","stable_key":"773f772e-bf8e-5e52-a2a2-6dd694d67f5d:bromelain-diabetes-rct-null-event","event_type":"observed_relationship","label":"In 68 adults with diabetes, 1050 mg/day bromelain for 12 weeks did not significantly improve fibrinogen, lipids, blood pressure, glucose, C-reactive protein, or anthropometric measures versus placebo.","description":"In 68 adults with diabetes, 1050 mg/day bromelain for 12 weeks did not significantly improve fibrinogen, lipids, blood pressure, glucose, C-reactive protein, or anthropometric measures versus placebo.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6a3990e6-85af-58c7-8087-8a251db842fa","slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"85b123d4-03ab-5e8e-98c3-03faec633ea6","slug":"human-diabetes-cardiovascular-risk-panel","display_name":"Cardiovascular risk markers in adults with diabetes","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Bromelain 1050 mg/day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"12 weeks","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Sixty-eight Chinese adults with diabetes and at least one cardiovascular risk factor","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Baseline fibrinogen differed despite randomization; the result is a clinical null for the tested dose and population, not proof of no effect in every setting.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Bromelain chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"}},{"dimension":"organism","value_text":"Sixty-eight Chinese adults with diabetes and at least one cardiovascular risk factor","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"In 68 adults with diabetes, 1050 mg/day bromelain for 12 weeks did not significantly improve fibrinogen, lipids, blood pressure, glucose, C-reactive protein, or anthropometric measures versus placebo.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial. (2016). https://pubmed.ncbi.nlm.nih.gov/27412590/ DOI: 10.1007/s11655-016-2521-2","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Randomized double-blind placebo-controlled trial","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"c95583ea-ff8e-5c6b-98f5-52b981e89244","evidence_kind":"source_excerpt","locator":"Lines 132-141","start_line":132,"end_line":141,"excerpt":"## bromelain-diabetes-rct-null\nIn 68 adults with diabetes, 1050 mg/day bromelain for 12 weeks did not significantly improve fibrinogen, lipids, blood pressure, glucose, C-reactive protein, or anthropometric measures versus placebo.\nModel/species: Sixty-eight Chinese adults with diabetes and at least one cardiovascular risk factor\nTissue/system: Randomized double-blind placebo-controlled trial\nExposure: Bromelain 1050 mg/day\nRoute: Oral\nDuration: 12 weeks\nLimits: Baseline fibrinogen differed despite randomization; the result is a clinical null for the tested dose and population, not proof of no effect in every setting.\nPrimary reference: Bromelain and cardiovascular risk factors in diabetes: An exploratory randomized, placebo controlled, double blind clinical trial. (2016). https://pubmed.ncbi.nlm.nih.gov/27412590/ DOI: 10.1007/s11655-016-2521-2\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Sixty-eight Chinese adults with diabetes and at least one cardiovascular risk factor","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9d363b4e-f438-5664-9d74-99c2e359391d","stable_key":"import-773f772e-bf8e-5e52-a2a2-6dd694d67f5d","title":"Bromelain: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"b328dbb8082bea612bb2c40d6ff41fa670f6e62f714bd014c90627fcab86e95b","revision_id":"1c10d22e-ecdf-56ef-b820-bb21182a9577","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}